Call participants
Amy Janke, PhD – Chair
Barb Resnick, PhD
Kristin L. Schneider, PhD
Sandra Winter, PhD
Rebecca Bartlett Ellis, PhD (Guest, DHC liaison)
Leslie Hausmann, PhD

Regrets
Jeffrey P. Haibach, PhD, MPH
Colleen McBride, PhD
Jennifer A. Sumner, PhD
Julie E. Volkman, PhD
Sandra Winter, PhD
Tammy Schuler

Minutes Approval and Announcements
● Approved the November Meeting Minutes: https://docs.google.com/document/d/1ObLfifaijMOO7qQJyWkLdAVxF52fn5pr54qYTjn4D3o/edit
● Introduction of Tammy Schuler [tabled to next meeting]
  ○ Help with collaborations in the cancer area ie Cancer SIG
● In person meeting at the Annual Meeting: Thursday, April 2nd at 12:45-1:45. Please mark your calendars to attend if possible!
● Council call times revisited
  ○ Keep this call time, as it works with most everyone. Will revisit in about 6 months
● Google drive file organization
  ○ Sharing relevant material with the council via google drives. If you would like to house shareable materials such as partnering agreements, mou’s, or anything you’d like to share, you can do so in the google drive.

HERO Partnering Agreement
● HERO partnering agreement draft
● Action item: Agree on language and move up as needed for approvals

TOS partnership update
● MOU with toss was signed last year. Symposium was put together back in November to discuss goals that Tos and SBM have in common. Encouraged TOS to submit something to SBM so they can present within SBM- it was approved
● When they put together their annual meeting, they meet as a group and they invite their partners to submit ideas.
I ideas that were sent to TOS-
  ○ The policy work that SBM was doing, discussing how we can have a presentation on why you should get in policy work around obesity, how to get into policy work, Dr. Buscemi present her policy work on childhood obesity.
  ○ The other submission is about personalized medicine around obesity
  ○ The policy idea was something they wanted to do, but wanted to turn it into a keynote speaker presentation. They asked if SBM would be interested in co-sponsoring the keynote speaker presentation. SBM would have more of a support role- If someone would help and join conference calls closer to April. Will wait to move forward after presenting to the Executive Committee

Ongoing Discussion of Guidance Document
  ● [https://docs.google.com/document/d/16TgkTyhUwX7GcxHiU2VNRGyfqmqwXu7dS_BxoOSkotE/edit](https://docs.google.com/document/d/16TgkTyhUwX7GcxHiU2VNRGyfqmqwXu7dS_BxoOSkotE/edit)
  ● Levels of collaboration for partnership: document to review, discuss, and finalize here
    ○ Does it capture what SPLC does?
    ○ Are Scientific, Education, and/or Clinical Partner all on the same level? Do they require the same things, should they be in the same category?- Most of our partnerships are scientifically focused, but wanted to include education and clinical partnerships. Maybe separate them into categories instead of set categories, or categorize the levels such as 2a, 2b etc...
    ○ Review cycle: Initial 1 year and then every 3 years. The first year can be used as a trial run to determine where it best fits with SPLC
    ○ Should SPLC have a formal role for tier 1, should they happen w/o engagement?
      ■ Is it worth to have this tier go through an MOU

  ● How should we define the partnerships: Define by the initial category for the trial year then see where it fits best
  ● Partnerships in need of evaluation: list for 2020 evaluation
  ● What’s the process for liaisons that form/maintain outside of SPLC but the SPLC should know about/manage?
    ○ Assign your liaison with a level and assign a rubric
    ○ Have ideas/forms ready by the annual meeting, and we can present them to the board.
    ○ Amy will send within a few days specific liaisons and what their roles are.
Other updates??

Meeting Adjourned: 2:57